116 related articles for article (PubMed ID: 15970176)
1. [Pharmacokinetics/pharmacodynamics of the 1000/62.5 formulation of amoxicillin/clavulanic acid in odontostomatology].
Isla A; Canut A; Rodríguez Gascón A; Pedraz JL
Enferm Infecc Microbiol Clin; 2005; 23(6):387. PubMed ID: 15970176
[No Abstract] [Full Text] [Related]
2. Amoxicillin/clavulanic acid (875/125): bioequivalence of a novel Solutab tablet and rationale for a twice-daily dosing regimen.
Sourgens H; Bertola MA; Verschoor JS; Kuipers M; Rayer B
Int J Clin Pharmacol Ther; 2004 Mar; 42(3):165-73. PubMed ID: 15049437
[TBL] [Abstract][Full Text] [Related]
3. [Sinusal penetration of amoxicillin-clavulanic acid. Formulation 1 g./125 mg., twice daily versus formulation 500 mg./125 mg., three times daily].
Jehl F; Klossek JM; Peynegre R; Serrano E; Castillo L; Bobin S; Desprez D; Renault C; Neel V; Rouffiac E; Borie C
Presse Med; 2002 Oct; 31(34):1596-603. PubMed ID: 12426976
[TBL] [Abstract][Full Text] [Related]
4. Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of Clavubactin and Synulox in healthy dogs.
Vree TB; Dammers E; Van Duuren E
J Vet Pharmacol Ther; 2003 Jun; 26(3):165-71. PubMed ID: 12755899
[TBL] [Abstract][Full Text] [Related]
5. [Amoxicillin/clavulanic acid (875/125 mg). New pharmacodynamic aspects].
Lode H
Dtsch Med Wochenschr; 1999 Dec; 124(48):1459-61. PubMed ID: 10615328
[No Abstract] [Full Text] [Related]
6. Variable absorption of clavulanic acid after an oral dose of 25 mg/kg of Clavubactin and Synulox in healthy cats.
Vree TB; Dammers E; van Duuren E
ScientificWorldJournal; 2002 May; 2():1369-78. PubMed ID: 12805922
[TBL] [Abstract][Full Text] [Related]
7. Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: use of replicate design approach.
Idkaidek NM; Al-Ghazawi A; Najib NM
Biopharm Drug Dispos; 2004 Dec; 25(9):367-72. PubMed ID: 15495146
[TBL] [Abstract][Full Text] [Related]
8. The clinical pharmacology of amoxicillin and clavulanic acid.
Reed MD
Pediatr Infect Dis J; 1998 Oct; 17(10):957-62. PubMed ID: 9802653
[No Abstract] [Full Text] [Related]
9. Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects.
Vree TB; Dammers E; Exler PS
J Antimicrob Chemother; 2003 Feb; 51(2):373-8. PubMed ID: 12562705
[TBL] [Abstract][Full Text] [Related]
10. A new amoxicillin/clavulanate therapeutic system: preparation, in vitro and pharmacokinetic evaluation.
Kerč J; Opara J
Int J Pharm; 2007 Apr; 335(1-2):106-113. PubMed ID: 17141985
[TBL] [Abstract][Full Text] [Related]
11. Augmentin XR.
Med Lett Drugs Ther; 2003 Jan; 45(1148):5-6. PubMed ID: 12571540
[No Abstract] [Full Text] [Related]
12. Elements of design: the knowledge on which we build.
MacGowan AP
Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():6-11. PubMed ID: 14759228
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
MacGowan AP; Noel AR; Rogers CA; Bowker KE
Antimicrob Agents Chemother; 2004 Jul; 48(7):2599-603. PubMed ID: 15215115
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence of clavulanate potassium and amoxicillin (1:7) dispersible tablets in healthy volunteers.
Hu G; Dai Z; Long L; Han Y; Hou S; Wu L
J Huazhong Univ Sci Technolog Med Sci; 2002; 22(3):224-7. PubMed ID: 12658810
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo 12 h bactericidal activity of oral co-amoxiclav (1.125 g) against beta-lactamase-producing Haemophilus influenzae.
Bronner S; Pompei D; Elkhaïli H; Dhoyen N; Monteil H; Jehl F
J Antimicrob Chemother; 2001 Oct; 48(4):501-6. PubMed ID: 11581228
[TBL] [Abstract][Full Text] [Related]
16. Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.
Easton J; Noble S; Perry CM
Drugs; 2003; 63(3):311-40. PubMed ID: 12534334
[TBL] [Abstract][Full Text] [Related]
17. [Choice of antibiotics in lower respiratory infections: what does pharmacodynamics bring? Clinical application of pharmacodynamic data].
Goldstein F
Presse Med; 1998 Sep; 27 Suppl 4():22-3. PubMed ID: 9798483
[No Abstract] [Full Text] [Related]
18. In vitro bactericidal activity of peak serum concentrations of co-amoxiclav, amoxicillin and vancomycin against methicillin-resistant Staphylococcus aureus.
Gómez-Lus ML; Prieto J; Giménez MJ; García M; Anta L; Aguilar L
Rev Esp Quimioter; 1999 Jun; 12(2):136-9. PubMed ID: 10562674
[TBL] [Abstract][Full Text] [Related]
19. [What pharmacodynamic elements affect Augmentin in man?].
Jehl F
Presse Med; 1998 Sep; 27 Suppl 4():20-1. PubMed ID: 9798482
[No Abstract] [Full Text] [Related]
20. In vitro combined effect of co-amoxiclav concentrations achievable in serum after a 2000/125 mg oral dose, and polymorphonuclear neutrophils against strains of Streptococcus pneumoniae exhibiting decreased susceptibility to amoxicillin.
Amores R; Alou L; Giménez MJ; Sevillano D; Gómez-Lus ML; Aguilar L; Prieto J
Int J Antimicrob Agents; 2004 Jul; 24(1):79-82. PubMed ID: 15225866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
